MindBio Therapeutics Corp. said that “MB22001, a proprietary and self-titratable form of Lysergic Acid Diethylamide (LSD) designed for safe take home microdosing” has been approved for take-home use ...
Australian R&D company MindBio Therapeutics conducted a first-ever Phase 2a take-home microdosing trial to treat depression.. 53% of patients went into complete depression remission after 8 weeks of ...
Better moods, higher concentration levels, more creativity - and all without the usual risks associated with hard drugs: Proponents of microdosing LSD - taking tiny fractions of the amount needed for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback